RGBP · OTC · Life Sciences
$0.0001
0.0% close Oct 30
The story so far · updated with every event
Regen BioPharma is funding itself through a discounted note and a $10,000,000 equity line while carrying 2,029,228,670 shares outstanding. The company reported $239 of cash in its August 10-Q, so the terms of each draw and any default conversion will shape the share count from here.
latest
Regen raised $112,500 net from a discounted note and signed a $10,000,000 equity line.
history
Five prior financing days averaged a 2.2% next day decline, and all five were below start after ten sessions.
insiders
No open market buys or sells appear in the 90 days before this event.
Each dot is an event day scored 8 or higher, coloured by type. Hover one to see what happened and how RGBP reacted.
Events
Last time: Going concern doubt, heavy dilution and a critical cash shortage reported by Regen BioPharma · May 14 · 0.0% next day
Read the full story →Last time: Debt settled by Regen BioPharma with 77.8M shares issued, diluting holders 36% · Mar 4 · 0.0% next day
Filing on SEC EDGAR →Last time: Going concern doubt, heavy dilution and ineffective controls noted by Regen BioPharma · Feb 13 · 0.0% next day
Filing on SEC EDGAR →Last time: Regen BioPharma issues shares to retire debt and bring in capital · Feb 2 · ▼ 14.04% next day
Filing on SEC EDGAR →Last time: Regen BioPharma declares dividend on preferred stock for all shareholders · Jan 21 · ▲ 16.67% next day
Filing on SEC EDGAR →Last time: Going concern flagged as Regen BioPharma files $450K Reg A at deep discount · Jan 8 · ▼ 13.58% next day, back to its starting price in 11 sessions
Filing on SEC EDGAR →9 events on record.
Last time, by type
Average next day move, close to close, after every RGBP event scored 7 or higher since Jan 2026, by type, biggest first. Only types with 3 or more event days are shown.
Financials
10-K for the period ended Sep 30, 2025, from SEC EDGAR
Revenue
$236.6K
Net income
minus $1.3M
Cash
$69.6K
Shares out
39.4M
About
Regen, incorporated on April 24, 2012, focuses on developing regenerative medical applications. The company aims to license, internally develop, or acquire these applications up to the successful completion of Phase I and/or Phase II clinical trials.
Every figure on this page is computed from the underlying data and checked before publishing. Not investment advice.